[go: up one dir, main page]

BR9711988A - Matrix metalloproteinase inhibitors and their therapeutic uses - Google Patents

Matrix metalloproteinase inhibitors and their therapeutic uses

Info

Publication number
BR9711988A
BR9711988A BR9711988A BR9711988A BR9711988A BR 9711988 A BR9711988 A BR 9711988A BR 9711988 A BR9711988 A BR 9711988A BR 9711988 A BR9711988 A BR 9711988A BR 9711988 A BR9711988 A BR 9711988A
Authority
BR
Brazil
Prior art keywords
matrix metalloproteinase
therapeutic uses
metalloproteinase inhibitors
inhibitors
therapeutic
Prior art date
Application number
BR9711988A
Other languages
Portuguese (pt)
Inventor
Patrick Michael O'brien
Joseph Armand Picard
Drago Robert Sliskovic
Andrew David White
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9711988A publication Critical patent/BR9711988A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
BR9711988A 1996-09-04 1997-08-22 Matrix metalloproteinase inhibitors and their therapeutic uses BR9711988A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2506296P 1996-09-04 1996-09-04
US5571397P 1997-08-07 1997-08-07
PCT/US1997/014859 WO1998009934A1 (en) 1996-09-04 1997-08-22 Matrix metalloproteinase inhibitors and their therapeutic uses

Publications (1)

Publication Number Publication Date
BR9711988A true BR9711988A (en) 1999-08-24

Family

ID=26699216

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711988A BR9711988A (en) 1996-09-04 1997-08-22 Matrix metalloproteinase inhibitors and their therapeutic uses

Country Status (8)

Country Link
EP (1) EP0931045A1 (en)
JP (1) JP2000517341A (en)
KR (1) KR20000068414A (en)
AU (1) AU735013B2 (en)
BR (1) BR9711988A (en)
CA (1) CA2256716A1 (en)
NZ (1) NZ333063A (en)
WO (1) WO1998009934A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736347B2 (en) 1996-09-04 2001-07-26 Warner-Lambert Company Compounds for and a method of inhibiting matrix metalloproteinases
CA2263886A1 (en) * 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
CZ2001126A3 (en) * 1998-07-21 2002-01-16 Warner-Lambert Company Common effects of ACAT and MMP inhibitors in the treatment of atherosclerotic lesions
AU4229499A (en) * 1998-07-30 2000-02-21 Warner-Lambert Company Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
PT1100792E (en) 1998-07-30 2004-08-31 Warner Lambert Co TRICYCLIC SULFONAMID AND ITS DERIVATIVES AS MATRIX METALOPROTEINASE INHIBITORS
WO2000015213A1 (en) * 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure
CN1366524A (en) 2000-04-07 2002-08-28 三星电子株式会社 Sulfonamide Derivatives as Matrix Metalloproteinase Inhibitors
MXPA01013172A (en) 2001-02-14 2002-08-21 Warner Lambert Co Sulfonamide matrix metalloproteinase inhibitors.
AR035455A1 (en) * 2001-04-23 2004-05-26 Hoffmann La Roche TRICYCLE DERIVATIVES OF ALQUILHIDROXAMATO, PROCESSES FOR THEIR DEVELOPMENT, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THE USE OF SUCH COMPOUNDS IN THE PREPARATION OF MEDICINES
AU2003269317B2 (en) * 2002-10-23 2009-10-29 Glenmark Pharmaceuticals Ltd. Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2004089940A1 (en) * 2003-04-11 2004-10-21 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2004111044A1 (en) * 2003-06-17 2004-12-23 Glenmark Pharmaceuticals Ltd. Tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation
JP2009519206A (en) 2004-10-13 2009-05-14 グレンマーク・ファーマシューティカルズ・エスエー Process for producing N- (3,5-dichloropyridin-4-yl) -4-difluoromethoxy-8-methanesulfonamido-dibenzo [B, D] furan-1-carboxamide
ES2417491T3 (en) 2004-12-17 2013-08-08 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
AR066386A1 (en) 2004-12-17 2009-08-19 Glenmark Pharmaceuticals Sa CONDENSED HETEROCICLICAL COMPOUNDS, METHODS AND INTERMEDIARIES FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE IN THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF PDE-4
WO2008057254A2 (en) * 2006-10-27 2008-05-15 Wyeth Tricyclic compounds as matrix metalloproteinase inhibitors
CL2008001257A1 (en) * 2007-05-04 2008-07-04 Wyeth Corp TRICYCLE COMPOUNDS, INHIBITORS OF MARRIAGE METALOPROTEINASES; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS REUMATOID ARTHRITIS, OSTEOARTHRITIS, ATEROSCLEROSIS, LUNG CANCER, AMONG OTHERS.
CN105906665B (en) * 2016-05-16 2017-11-28 中国医学科学院医药生物技术研究所 Carbazole sulfonamide derivative prodrug or its officinal salt and its preparation method and application
WO2021147882A1 (en) * 2020-01-21 2021-07-29 深圳信立泰药业股份有限公司 Dibenzofuran derivative cathepsin k inhibitor, preparation method therefor and medical use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2065966C3 (en) * 1969-09-06 1978-11-16 Ajinomoto Co., Inc., Tokio N-fluorenyl-sulfonyl-aminocarboxylic acids and agents containing them
US3845097A (en) * 1969-09-06 1974-10-29 Ajinomoto Kk N-substituted amino acids and novel ester
NL7013043A (en) * 1969-09-06 1971-03-09
US4097472A (en) * 1974-11-08 1978-06-27 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
EP0183271B1 (en) * 1984-11-30 1990-05-16 Shosuke Okamoto Lysin derivative and proteinase inhibitor
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
JPH11506097A (en) * 1995-06-02 1999-06-02 ワーナー−ランバート・コンパニー Tricyclic inhibitors of matrix metalloproteinases
PT874836E (en) * 1995-11-17 2003-02-28 Warner Lambert Co SULFONAMIDE INHIBITORS OF MATRIX METALOPROTEINSES
KR100338857B1 (en) * 1996-01-23 2002-05-30 시오노 요시히코 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same

Also Published As

Publication number Publication date
CA2256716A1 (en) 1998-03-12
EP0931045A1 (en) 1999-07-28
JP2000517341A (en) 2000-12-26
KR20000068414A (en) 2000-11-25
AU4159597A (en) 1998-03-26
NZ333063A (en) 2000-12-22
AU735013B2 (en) 2001-06-28
WO1998009934A1 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
BR9711988A (en) Matrix metalloproteinase inhibitors and their therapeutic uses
FI972160A7 (en) Matrix metalloprotease inhibitors
NO994438L (en) Therapeutically active diarylpropylamines and their preparation and use
NO20000125D0 (en) Tiadiazolyl and oxadiazolylphenyloxazolidinone antibacterial agents
NO991922D0 (en) Heteroarlsuccinamides and their use as metalloproteinase inhibitors
BR9601693A (en) Composition and its uses
BR9812128B8 (en) CATHETER IV AND CATHETER DEVICE
NO20001323D0 (en) Dipeptide-apoptosis inhibitors and their use
FI965019A7 (en) Enzyme inhibitors
BR9506832A (en) N-pyrazolylanilines and n-pyrazolylaminopyridines
BR9709902A (en) Matrix metalloproteinase inhibitors
DE59710593D1 (en) therapy device
DE59711085D1 (en) therapy device
DK0885437T3 (en) Display Device and Array
DE59609922D1 (en) ACTIVE COMBINATIONS
BR9707770A (en) Tifluzamide with improved efficacy
DE69524667D1 (en) memory array
ID22281A (en) SUBSTITUTIONAL PROPIONIL DEGREES
AU7502696A (en) Matrix metalloproteinase inhibitors and their therapeutic use
NO971333D0 (en) Control and control plugs
GB9702085D0 (en) Matrix metalloproteinase inhibitors
KR960031471U (en) Magnetized Hexagonal Device
KR960020229U (en) Portable chessboard and checkerboard
NO995985D0 (en) New carbohydrates and their use
ID17775A (en) BIFENYL BUTIRAT ACID AND ITS DECREASED INHIBITOR METALOPROTEINASE MATRIX

Legal Events

Date Code Title Description
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1945 DE 15/04/2008.